Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention—quality metric and opportunities for quality improvement

Society for Maternal-Fetal Medicine (SMFM), SMFM Patient Safety and Quality Committee

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia. Despite recommendations from the US Preventive Services Task Force, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine, low-dose aspirin use is reported in <50% of patients with high-risk factors and <25% of patients with >1 moderate-risk factor. These low use rates represent an important “quality gap” and demonstrate the need for quality improvement activities. In this article, we outline the specifications for a process metric to standardize the measurement of the rate of aspirin use. Furthermore, we outline an approach to conducting a quality improvement project to increase the use of aspirin by patients with risk factors for preeclampsia.

Original languageEnglish (US)
Pages (from-to)B2-B9
JournalAmerican journal of obstetrics and gynecology
Volume229
Issue number2
DOIs
StatePublished - Aug 2023

Keywords

  • antiphospholipid syndrome
  • diabetes mellitus (pregestational)
  • fetal growth restriction
  • hypertension
  • kidney disease
  • multifetal pregnancy
  • preterm birth
  • risk factors
  • screening
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention—quality metric and opportunities for quality improvement'. Together they form a unique fingerprint.

Cite this